Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genfit SA
Common Shares Outstanding
Genfit SA
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Common Shares Outstanding
€50m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Valneva SE
PAR:VLA
|
Common Shares Outstanding
€173.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Inventiva SA
PAR:IVA
|
Common Shares Outstanding
€193.2m
|
CAGR 3-Years
66%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Common Shares Outstanding
$72.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
DBV Technologies SA
PAR:DBV
|
Common Shares Outstanding
$235.6m
|
CAGR 3-Years
36%
|
CAGR 5-Years
34%
|
CAGR 10-Years
26%
|
|
|
Abivax SA
PAR:ABVX
|
Common Shares Outstanding
€78.5m
|
CAGR 3-Years
52%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Common Shares Outstanding?
Common Shares Outstanding
50m
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's Common Shares Outstanding amounts to 50m EUR.
What is Genfit SA's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
7%
Over the last year, the Common Shares Outstanding growth was 0%.
